A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma

Atsushi Hongo, Tomoyuki Kusumoto, Keiichiro Nakamura, Noriko Seki, Junichi Kodama, Yuji Hiramatsu

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Although anthracyclines are considered as being among the most potent chemotherapeutic agents for endometrial carcinoma, the majority of institutions in Japan prefer a combination of paclitaxel and carboplatin (TC) for treating this disease. We retrospectively evaluated the efficacy and feasibility of combined paclitaxel, pirarubicin, and carboplatin (TPC) therapy for endometrial carcinoma. Methods: Thirty-nine patients with high/intermediate postoperative recurrence risks or with advanced disease received combination chemotherapy consisting of paclitaxel (150 mg/m2), pirarubicin (35 mg/m2), and carboplatin [area under the concentration time curve (AUC = 4)] from 2001 to 2006 at Okayama University Hospital. Treatment cycles were repeated every 3 weeks, and three to nine cycles were administered according to patient risk. Results: The 1-year overall survival (OS) and progression-free survival (PFS) rates were 94.9% and 84.6%, respectively, and the 3-year OS and PFS rate was 81.3%. Hematologic toxicities >grade 3 were: anemia 30.8%; leukopenia 84.6%; thrombocytopenia 20.5%. Neutropenia was common, and administration of granulocyte colony-stimulating factor (G-CSF) was necessary in 87.9% of treatment courses. Although grade 3 or 4 neutropenia was unavoidable, we could administer TPC therapy safely and without delay with G-CSF support. Gastrointestinal and neurological toxicity were less severe and less frequent compared with TC, and no cardiac toxicity was observed. Conclusion: The 3-year PFS and OS rates even in high-risk patients were satisfactory, and we confirmed the feasibility of using this regimen for treating endometrial carcinoma.

Original languageEnglish
Pages (from-to)476-483
Number of pages8
JournalInternational Journal of Clinical Oncology
Volume15
Issue number5
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Carboplatin
Endometrial Neoplasms
Paclitaxel
Combination Drug Therapy
Disease-Free Survival
Survival Rate
Granulocyte Colony-Stimulating Factor
Neutropenia
Survival
Anthracyclines
Leukopenia
Therapeutics
Thrombocytopenia
Area Under Curve
Anemia
Japan
Recurrence
pirarubicin

Keywords

  • Endometrial cancer
  • TPC therapy

ASJC Scopus subject areas

  • Oncology
  • Surgery
  • Hematology

Cite this

A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma. / Hongo, Atsushi; Kusumoto, Tomoyuki; Nakamura, Keiichiro; Seki, Noriko; Kodama, Junichi; Hiramatsu, Yuji.

In: International Journal of Clinical Oncology, Vol. 15, No. 5, 10.2010, p. 476-483.

Research output: Contribution to journalArticle

Hongo, Atsushi ; Kusumoto, Tomoyuki ; Nakamura, Keiichiro ; Seki, Noriko ; Kodama, Junichi ; Hiramatsu, Yuji. / A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma. In: International Journal of Clinical Oncology. 2010 ; Vol. 15, No. 5. pp. 476-483.
@article{8a5a826a15864b21b7df9e72877c2207,
title = "A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma",
abstract = "Background: Although anthracyclines are considered as being among the most potent chemotherapeutic agents for endometrial carcinoma, the majority of institutions in Japan prefer a combination of paclitaxel and carboplatin (TC) for treating this disease. We retrospectively evaluated the efficacy and feasibility of combined paclitaxel, pirarubicin, and carboplatin (TPC) therapy for endometrial carcinoma. Methods: Thirty-nine patients with high/intermediate postoperative recurrence risks or with advanced disease received combination chemotherapy consisting of paclitaxel (150 mg/m2), pirarubicin (35 mg/m2), and carboplatin [area under the concentration time curve (AUC = 4)] from 2001 to 2006 at Okayama University Hospital. Treatment cycles were repeated every 3 weeks, and three to nine cycles were administered according to patient risk. Results: The 1-year overall survival (OS) and progression-free survival (PFS) rates were 94.9{\%} and 84.6{\%}, respectively, and the 3-year OS and PFS rate was 81.3{\%}. Hematologic toxicities >grade 3 were: anemia 30.8{\%}; leukopenia 84.6{\%}; thrombocytopenia 20.5{\%}. Neutropenia was common, and administration of granulocyte colony-stimulating factor (G-CSF) was necessary in 87.9{\%} of treatment courses. Although grade 3 or 4 neutropenia was unavoidable, we could administer TPC therapy safely and without delay with G-CSF support. Gastrointestinal and neurological toxicity were less severe and less frequent compared with TC, and no cardiac toxicity was observed. Conclusion: The 3-year PFS and OS rates even in high-risk patients were satisfactory, and we confirmed the feasibility of using this regimen for treating endometrial carcinoma.",
keywords = "Endometrial cancer, TPC therapy",
author = "Atsushi Hongo and Tomoyuki Kusumoto and Keiichiro Nakamura and Noriko Seki and Junichi Kodama and Yuji Hiramatsu",
year = "2010",
month = "10",
doi = "10.1007/s10147-010-0099-9",
language = "English",
volume = "15",
pages = "476--483",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - A pilot study of combination chemotherapy with paclitaxel, pirarubicin, and carboplatin (TPC) for endometrial carcinoma

AU - Hongo, Atsushi

AU - Kusumoto, Tomoyuki

AU - Nakamura, Keiichiro

AU - Seki, Noriko

AU - Kodama, Junichi

AU - Hiramatsu, Yuji

PY - 2010/10

Y1 - 2010/10

N2 - Background: Although anthracyclines are considered as being among the most potent chemotherapeutic agents for endometrial carcinoma, the majority of institutions in Japan prefer a combination of paclitaxel and carboplatin (TC) for treating this disease. We retrospectively evaluated the efficacy and feasibility of combined paclitaxel, pirarubicin, and carboplatin (TPC) therapy for endometrial carcinoma. Methods: Thirty-nine patients with high/intermediate postoperative recurrence risks or with advanced disease received combination chemotherapy consisting of paclitaxel (150 mg/m2), pirarubicin (35 mg/m2), and carboplatin [area under the concentration time curve (AUC = 4)] from 2001 to 2006 at Okayama University Hospital. Treatment cycles were repeated every 3 weeks, and three to nine cycles were administered according to patient risk. Results: The 1-year overall survival (OS) and progression-free survival (PFS) rates were 94.9% and 84.6%, respectively, and the 3-year OS and PFS rate was 81.3%. Hematologic toxicities >grade 3 were: anemia 30.8%; leukopenia 84.6%; thrombocytopenia 20.5%. Neutropenia was common, and administration of granulocyte colony-stimulating factor (G-CSF) was necessary in 87.9% of treatment courses. Although grade 3 or 4 neutropenia was unavoidable, we could administer TPC therapy safely and without delay with G-CSF support. Gastrointestinal and neurological toxicity were less severe and less frequent compared with TC, and no cardiac toxicity was observed. Conclusion: The 3-year PFS and OS rates even in high-risk patients were satisfactory, and we confirmed the feasibility of using this regimen for treating endometrial carcinoma.

AB - Background: Although anthracyclines are considered as being among the most potent chemotherapeutic agents for endometrial carcinoma, the majority of institutions in Japan prefer a combination of paclitaxel and carboplatin (TC) for treating this disease. We retrospectively evaluated the efficacy and feasibility of combined paclitaxel, pirarubicin, and carboplatin (TPC) therapy for endometrial carcinoma. Methods: Thirty-nine patients with high/intermediate postoperative recurrence risks or with advanced disease received combination chemotherapy consisting of paclitaxel (150 mg/m2), pirarubicin (35 mg/m2), and carboplatin [area under the concentration time curve (AUC = 4)] from 2001 to 2006 at Okayama University Hospital. Treatment cycles were repeated every 3 weeks, and three to nine cycles were administered according to patient risk. Results: The 1-year overall survival (OS) and progression-free survival (PFS) rates were 94.9% and 84.6%, respectively, and the 3-year OS and PFS rate was 81.3%. Hematologic toxicities >grade 3 were: anemia 30.8%; leukopenia 84.6%; thrombocytopenia 20.5%. Neutropenia was common, and administration of granulocyte colony-stimulating factor (G-CSF) was necessary in 87.9% of treatment courses. Although grade 3 or 4 neutropenia was unavoidable, we could administer TPC therapy safely and without delay with G-CSF support. Gastrointestinal and neurological toxicity were less severe and less frequent compared with TC, and no cardiac toxicity was observed. Conclusion: The 3-year PFS and OS rates even in high-risk patients were satisfactory, and we confirmed the feasibility of using this regimen for treating endometrial carcinoma.

KW - Endometrial cancer

KW - TPC therapy

UR - http://www.scopus.com/inward/record.url?scp=78149361419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149361419&partnerID=8YFLogxK

U2 - 10.1007/s10147-010-0099-9

DO - 10.1007/s10147-010-0099-9

M3 - Article

VL - 15

SP - 476

EP - 483

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -